miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• MicroRNA-125a (miR-125a) is frequently downregulated in human cancers.
• The precise mechanisms by which reduced miR-125a contributes to cancer progression are not fully understood.
• Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells.

Purpose of the Study:

• To investigate the role of miR-125a in the proliferation and apoptosis of multiple myeloma (MM).
• To identify the molecular targets of miR-125a in MM.
• To evaluate the therapeutic potential of miR-125a restoration in MM.

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) to assess miR-125a expression levels in MM tissues and cell lines.
• In vitro experiments involving overexpression of miR-125a in MM cell lines (NCI-H929, U266) to evaluate effects on cell viability, colony formation, and apoptosis.
• In vivo studies using a mouse xenograft model of MM to assess the impact of miR-125a overexpression on tumor growth.
• Luciferase reporter assays and Western blotting to confirm USP5 as a direct transcriptional target of miR-125a.

Main Results:

• miR-125a expression was significantly reduced in MM tissues and cell lines compared to normal controls.
• Overexpression of miR-125a inhibited MM cell viability and colony formation, inducing apoptosis in miR-125a-deficient MM cells.
• Ubiquitin-specific peptidase 5 (USP5) was identified as a direct transcriptional target repressed by miR-125a.
• Re-expression of USP5 reversed the anti-proliferative effects of miR-125a in MM cells.
• In vivo, miR-125a overexpression suppressed MM tumor growth and reduced USP5 expression in tumor tissues.

Conclusions:

• miR-125a functions as a tumor suppressor in multiple myeloma by inhibiting cell proliferation and promoting apoptosis.
• miR-125a exerts its tumor-suppressive effects, at least in part, by directly repressing the expression of USP5.
• USP5 acts as an oncoprotein in the context of miR-125a deficiency in MM, highlighting its potential as a therapeutic target.